» Articles » PMID: 20723572

Urotensin II Alters Vascular Reactivity in Animals Subjected to Volume Overload

Overview
Journal Peptides
Specialty Biochemistry
Date 2010 Aug 21
PMID 20723572
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Congestive heart failure (CHF) alters vascular reactivity and up regulates in urotensin II (UTII), a potent vasoactive peptide. The aim of this study was to investigate the interaction between CHF and UTII in altering vascular reactivity in a rat model of volume overload heart failure. Animals were divided into 4 groups: control, UTII infused (UTII), volume overload only (VO) or volume overload+UTII (VO+UTII). Volume overload was established by the formation of an aortocaval fistula. Following fistula formation animals were administered UTII at a rate of 300 pmol/kg/h for 4 weeks subcutaneously with mini-osmotic pumps. Thoracic aorta rings, with/without endothelium, were subjected to cumulative dose-responses to phenylephrine, sodium nitroprusside (SNP), acetylcholine (ACH), UTII, and the Rho-kinase inhibitor HA-1077. Aortas from VO animals exhibited increased sensitivity to phenylephrine and UTII with a decreased relaxation response to ACH and HA-1077. Aortas from animals subjected to chronic UTII with volume overload (VO + UTII) retained their sensitivity to phenylephrine and UTII while they improved their relaxation to HA-1077 but not ACH. The constrictive response to UTII was dose-dependent and augmented at concentrations <0.01 μM in VO animals. The changes in vascular reactivity paralleled an elevation of both the UTII and α(1A)-adrenergic receptor while the Rho and Rho-kinase signalling proteins were diminished. We found that volume overload increased sensitivity to the vasoconstrictor agents that was inversely related to changes in the Rho-kinase expression. The addition of UTII with VO reversed the constrictive vascular response through alterations in the Rho-kinase signalling pathway.

Citing Articles

Signalling pathways involved in urotensin II induced ventricular myocyte hypertrophy.

Al Ali H, Rodrigo G, Lambert D PLoS One. 2025; 20(1):e0313119.

PMID: 39820183 PMC: 11737703. DOI: 10.1371/journal.pone.0313119.


Enhanced vascular neuronal nitric-oxide synthase-derived nitric-oxide production underlies the pressor response caused by peripheral N-methyl-D-aspartate receptor activation in conscious rats.

McGee M, Abdel-Rahman A J Pharmacol Exp Ther. 2012; 342(2):461-71.

PMID: 22580349 PMC: 11047766. DOI: 10.1124/jpet.112.194464.

References
1.
Harris G, Lust R, Katwa L . Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula. Peptides. 2007; 28(8):1483-9. PMC: 2965601. DOI: 10.1016/j.peptides.2007.04.018. View

2.
Christ G, Wingard C . Calcium sensitization as a pharmacological target in vascular smooth-muscle regulation. Curr Opin Investig Drugs. 2005; 6(9):920-33. View

3.
Tasaki K, Hori M, Ozaki H, Karaki H, Wakabayashi I . Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci. 2004; 94(4):376-83. DOI: 10.1254/jphs.94.376. View

4.
Loirand G, Guerin P, Pacaud P . Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006; 98(3):322-34. DOI: 10.1161/01.RES.0000201960.04223.3c. View

5.
Somlyo A, Somlyo A . Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000; 522 Pt 2:177-85. PMC: 2269761. DOI: 10.1111/j.1469-7793.2000.t01-2-00177.x. View